Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.62 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | PPARG | P37231 | 3/20 | 0.62 |
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.62 |
| ▸ | RXRA | P19793 | 2/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.62 |
| ▸ | CNR1 | P21554 | 2/20 | 0.54 |
| ▸ | F7 | P08709 | 3/20 | 0.53 |
| ▸ | F3 | P13726 | 3/20 | 0.53 |
| ▸ | PPARA | Q07869 | 3/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | PPARD | Q03181 | 2/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14359342 | 0.89 | ALDH1A1 (0.65) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL18250201 | 0.89 | ALDH1A1 (0.65) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL22673612 | 0.85 | ALDH1A1 (0.67) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL17676165 | 0.79 | ALDH1A1 (0.45) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL14958851 | 0.79 | ALDH1A1 (0.45) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL353829 | 0.79 | ALDH1A1 (0.72) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| SCHEMBL353830 | 0.79 | ALDH1A1 (0.72) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| Doconexent SCHEMBL18185516 | 0.77 | ALDH1A1 (1.00) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| Doconexent SCHEMBL18185492 | 0.77 | ALDH1A1 (1.00) | ALDH1A1CYP19A1MAPTPPARGOXER1 | |
| Doconexent SCHEMBL18274973 | 0.77 | ALDH1A1 (1.00) | ALDH1A1CYP19A1MAPTPPARGOXER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230058971-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-20230056284-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | Graybug Vision, Inc. (US) | 2023-01-10 | — | — | US | disclosed |
| US-11160870-B2 | Extended release microparticles and suspensions thereof for medical therapy | Graybug Vision, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200230246-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | Graybug Vision, Inc. (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | Graybug Vision, Inc. (US) | 2020-01-30 | — | — | US | disclosed |
| US-9604920-B2 | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome | ALAPATI MOHAN MURALI (IN) | 2017-03-28 | — | — | US | disclosed |
| US-20160272582-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERGLYCEMIA AND METABOLIC SYNDROME | ALAPATI MOHAN MURALI (IN) | 2016-09-22 | — | — | US | disclosed |
| US-9371276-B1 | Compositions and methods for the treatment of hyperglycemia and metabolic syndrome | ALAPATI MOHAN MURALI (IN) | 2016-06-21 | — | — | US | disclosed |
| US-8703804-B2 | Ryanodine receptor inhibitors and methods relating thereto | UTI LIMITED PARTNERSHIP (CA) | 2014-04-22 | — | — | US | disclosed |
| US-20070254849-A1 | Ryanodine receptor inhibitors and methods relating thereto | UTI LIMITED PARNERSHIP | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200031783-A1 | DRUGS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | PDE6C, PDE6A, PDE6D | ALDH1A1 1084/4885CYP19A1 2982/4885MAPT 212/4885 |
| US-11548861-B2 | Drugs and compositions for the treatment of ocular disorders | PDE6C, PDE6A, PDE6D | ALDH1A1 1084/4885CYP19A1 2982/4885MAPT 212/4885 |
| US-11160870-B2 | Extended release microparticles and suspensions thereof for medical therapy | CHMP4B, EXOSC9, EXOSC5 | ALDH1A1 2063/4885CYP19A1 2499/4885MAPT 1344/4885 |
| US-20160272582-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HYPERGLYCEMIA AND METABOLIC SYNDROME | GPR119, SLC5A1, SLC5A2 | ALDH1A1 1900/4885CYP19A1 591/4885MAPT 1920/4885 |
| US-20230058971-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | ALDH1A1 2063/4885CYP19A1 2499/4885MAPT 1344/4885 |
| US-20200230246-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | ALDH1A1 2063/4885CYP19A1 2499/4885MAPT 1344/4885 |
| US-20230056284-A1 | EXTENDED RELEASE MICROPARTICLES AND SUSPENSIONS THEREOF FOR MEDICAL THERAPY | CHMP4B, EXOSC9, EXOSC5 | ALDH1A1 2063/4885CYP19A1 2499/4885MAPT 1344/4885 |
| US-20070254849-A1 | Ryanodine receptor inhibitors and methods relating thereto | RYR2, RYR1, ATP2A1 | ALDH1A1 3262/4885CYP19A1 4238/4885MAPT 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.